RE:RE:RE:RE:RE:ONCY bispecific in development (pelareorep x CD3)westcoast1000, further to your point and in support of of Dr. von Monfoort's statement supporting the findings of the bisepecific study and other work that ONCY has conducted showing that pelareorep is synergistic with other forms of I/O cancer therapy including checkpoint inhibitors and CAR-T therapy for example, Dr. vaon Monfoort's work adds to the growing evidence that pelareorep in combination with other I/O agents (combination therapy) results in greater treatment effectiveness and treatment peristence, than either agent used alone (monotherapy).
Consequently the expected value of ONCY as a company is more in-line with the USD$8 Billion to USD$ 15 Billion, than anything that may have been cited otherwise or beforehand.